The Tribune Editorial: If manufacturers are unable to recover production costs, they may simply stop supplying these medicines.
THE decision of the National Pharmaceutical Pricing Authority (NPPA) to permit a 50% increase in the prices of select cancer drugs, anti-tetanus serum and childhood vaccines underscores the difficult choices inherent in public health policy. On the one hand lies the imperative of keeping essential medicines affordable in a country where a large proportion of households rely on out-of-pocket expenditure for healthcare. On the other lies the need to ensure that life-saving medicines remain available in the market. The steep rise in the prices of certain drugs and vaccines may be justifiable, but it raises questions about healthcare equity. The NPPA has cited concerns over shortages and escalating input costs. If manufacturers are unable to recover production costs, they may simply stop supplying these medicines.Yet this argument cannot obscure another reality: millions of people struggle to pay for even basic healthcare. A 50% increase in the price of medicines used to treat cancer or prevent childhood diseases can push vulnerable families deeper into financial distress. For patients, treatment expenses often extend beyond medicines to diagnostics, travel, hospitalisation and loss of income. Any additional burden can force difficult choices between treatment and survival. The answer, thus, does not lie in choosing between affordability and availability. It lies in building mechanisms that protect both.The government must strengthen public procurement and ensure uninterrupted supplies through public hospitals. Insurance schemes should expand coverage for essential medicines, while targeted subsidies can shield poor patients from sudden price shocks. At the same time, pricing policies should be reviewed periodically to reflect genuine increases in production costs and prevent shortages. Essential medicines cannot be treated as ordinary commodities.
